Management of women with cervical cytology interpreted as ASC-US or as ASC-H

Clinical Obstetrics and Gynecology

Volumn 48, Issue 1, 2005, Pages 160-177

  Cox, J Thomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ESTROGEN; VIRUS DNA;

ALGORITHM; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; COLPOSCOPY; CONFERENCE PAPER; CONSENSUS; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; DNA DETERMINATION; EVALUATION; FEMALE; FOLLOW UP; HUMAN; PATIENT COUNSELING; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; REPRODUCIBILITY; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS;

EID: 14844364644     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000151571.91814.f3     Document Type: Conference Paper

References (72)

1. Solomon D, Schiffman MH, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
2. Wright TC Jr, Cox JT, Massad LS, et al. 2001 consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
3. Wright TC Jr, Cox JT, Massad LS, et al, for the American Society for Colposcopy and Cervical Pathology. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2003;189:295-304.
4. Bogdanich W. The Pap test misses much cervical cancer through lab's efforts. Wall Street Journal. November 2, 1987:1.
5. Koss LG. The Papanicolaou test for cervical cancer detection: A triumph and a tragedy. JAMA. 1989;261:737-743.
6. Clinical Laboratory Improvement Amendments of 1988, 42 C.F.R. Part 405. 1992; 57:7169.
7. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnosis. JAMA. 1989;262:931-934.
8. Crothers BA. The Bethesda System 2001: update on terminology and application. Clin Obstet Gynecol. 2005;48:98-107.
9. Papanicolaou GN, Traut HF. Diagnosis of Uterine Cancer by the Vaginal Smear. New York, NY: Commonwealth Fund; 1943.
10. Cox JT, Lorincz AT, Schiffman MH, et al. HPV testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of ASCUS. Am J Obstet Gynecol. 1995;172:946-954.
11. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-1610.
12. Sherman ME, Schiffman M, Cox JT, et al, for the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2002;94: 102-107.
13. Braly P, Kinney W, Sheets E, et al. Reporting the potential benefits of new technologies for cervical cancer screening. J Lower Genit Tract Dis. 2000;5:73-81.
14. Ries LAG, Kosary CL, Hankey BF, et al, eds. SEER Cancer Statistics Review, 1973-1993: Tables and Graphs. Bethesda, MD: National Cancer Institute; 1996.
15. Ries LAG, Kosary CL, Hankey BF, et al, eds. SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute; 1999.
16. The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Report of the 1991 Bethesda Workshop. Am J Surg Pathol. 1992;16:914-916.
17. Kurman RJ, Henson D, Herbst A, et al. Interim guidelines for management of abnormal cervical cytology. JAMA. 1994;271:1866-1869.
18. Solomon D, Davey D, Kurman R, et al, Forum Group Members, The Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
19. Pitman MB, Cibas ES, Powers CN, et al. Reducing or eliminating use of the category of atypical squamous cells of undetermined significance decreases the diagnostic accuracy of the Papanicolaou smear. Cancer. 2002;96: 128-134.
20. Pirog EC, Erroll M, Harigopal M, et al. Comparison of human papillomavirus DNA prevalence in atypical squamous cells of undetermined significance subcategories as defined by the original Bethesda 1991 and the new Bethesda 2001 Systems. Arch Pathol Lab Med. 2004;128:527-532.
21. Sherman ME, Solomon D, Schiffman M, for the ALTS Group. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am J Clin Pathol. 2001;116:386-394.
22. Alli PM, Ali SZ. Atypical squamous cells of undetermined significance-rule out high-grade squamous intraepithelial lesion: cytopathologic characteristics and clinical correlates. Diagn Cytopathol. 2003;28:308-312.
23. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytology and histologic interpretations. Realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505.
24. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188: 1383-1392.
25. Sherman ME, Schiffman MH, Lorincz AT, et al. Toward objective quality assurance in cervical cytopathology: correlation of cytopathologic diagnosis with detection of high-risk human papillomavirus types. Am J Clin Pathol. 1994;102;182-187.
26. Smith AE, Sherman ME, Scott DR, et al. Review of the Bethesda System atlas does not improve reproducibility or accuracy in the classification of atypical squamous cells of undetermined significance. Cancer. 2000; 90:201-206.
27. Raffle AE, Alden B, MacKenzie EFD. Detection rates for abnormal cervical smears: What are we screening for? Lancet. 1995; 345:1469-1473.
28. Scheiden R, Wagener C, Knolle U, et al. Atypical squamous cells of undetermined significance: audit and the impact of potential litigation. Retrospective review of 682 cases. Cytopathology. 2003;14:257-262.
29. Cox JT. Editorial: evaluating the role of HPV testing for women with equivocal Papanicolaou test findings. JAMA. 1999;281:1645-1647.
30. Kinney WK, Manos MM, Hurley LB, et al. Where's the high grade cervical neoplasia? The importance of the minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998;91:973-976.
31. Gordon P, Hatch K. Survey of colposcopy practices by obstetrician/ gynecologists. J Reprod Med. 1992;37:861-863.
32. Wright TC, Lorincz AT, Ferris DG, et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Pap smears. Am J Obstet Gynecol. 1998; 178:962-966.
33. Cox JT, Schiffman M, Solomon D, for the ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406-1412.
34. Jones MH, Singer A, Jenkins D. The mildly abnormal cervical smear: patient awareness and choice of management. J R Soc Med. 1996;89:257-260.
35. Confortini M, Carozzi F, Dalla Palma P, et al, for the GISCi Working Group for Cervical Cytology. Interlaboratory reproducibility of atypical squamous cells of undetermined significance report: a national survey. Cytopathology. 2003;14:263-268.
36. Evidence Report/Technology Assessment: Number 5. Rockville, MD: Agency for Health Care Policy and Research; 1999.
37. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680-689.
38. Nygard JF, Sauer T, Skjeldestad FE, et al. CIN 2/3 and cervical cancer after an ASCUS pap smear. A 7-year, prospective study of the Norwegian population-based, coordinated screening program. Acta Cytol. 2003;47: 991-1000.
39. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004; 96:280-293.
40. Lytwyn A, Sellors JW, Mahony JB, et al. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med. 2003;127:1169-1175.
41. Robertson JH, Woodend BE, Crozier EH, et al. Risk of cervical cancer associated with mild dyskaryosis. Br Med J. 1988;297: 18-21.
42. Wright TC Jr, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. J Lower Genit Tract Dis. 2002;6: 127-143.
43. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
44. Ferris DG, Cox JT, O'Connor DM, et al. Modern Colposcopy. 2nd ed. Dubuque, IA: Kendall-Hunt; 2004:544-561.
45. Sherman ME. Chapter 11: Future directions in cervical pathology. J Natl Cancer Inst Monogr. 2003;31:72-79.
46. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol. 2001;185: 308-317.
47. Kim JJ, Wright TC, Goldie SJ. Cost effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382-2390.
48. Noller KL, Bettes B, Zinberg S, et al. Cervical cytology screening practices among obstetrician-gynecologists. Obstet Gynecol. 2003;102:259-265.
49. Lousuebsakul V, Knutsen SM, Singh PN, et al. Is colposcopic biopsy overused among women with a cytological diagnosis of atypical squamous cells of undetermined significance (ASCUS)? J Womens Health. 2003; 12:553-559.
50. Guido R, Schiffman M, Solomon D, et al, for the ASCUS LSIL Triage Study (ALTS) Group. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol. 2003;188:1401-1405.
51. Cox JT. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors. Arch Pathol Lab Med. 2003;127: 950-958.
52. Castle PE, Schiffman M, Burk RD, et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev. 2002;11:1394-1399.
53. Castle PE, Lorincz AT, Scott DR, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol. 2003;41:4022-4030.
54. Massad LS, Ahdieh L, Benning L, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2001;27:432-442.
55. Levi AW, Kelly DP, Rosenthal DL, et al. Atypical squamous cells of undetermined significance in liquid-based cytologic specimens: results of reflex human papillomavirus testing and histologic follow-up in routine practice with comparison of interpretive and probabilistic reporting methods. Cancer. 2003;99:191-197.
56. Anhang R, Goodman A, Goldie SJ. HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin. 2004;54:248-259.
57. Lozano R. Successfully integrating human papillomavirus testing into your practice. Arch Pathol Lab Med. 2003;127:991-994.
58. Selvaggi SM. Reporting of atypical squamous cells-cannot exclude a high-grade squamous intraepithelial lesion (ASC-H) on cervical samples: is it significant? Diagn Cytopathol. 2003;29:38-41.
59. Louro AP, Roberson J, Eltoum I, et al. A typical squamous cells, cannot exclude high-grade squamous intraepithelial lesion. A follow-up study of conventional and liquid-based preparations in a high-risk population. Am J Clin Pathol. 2003;120:392-397.
60. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55:244-265.
61. Nobbenhuis M, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354:20-25.
62. Giuliano AR, Papenfuss M, De Galaz EM, et al. Risk factors for squamous intraepithelial lesions (SIL) of the cervix among women residing at the US-Mexico border. Int J Cancer. 2004;109:112-118.
63. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 2002; 360:228-229.
64. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003;127:930-934.
65. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000; 92:464-474.
66. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 2000;355:2194-2198.
67. Sherman ME, Wang SS, Wheeler CM, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev. 2003;12:1038-1044.
68. Cox JT. Evaluation of abnormal cervical cytology. Clin Lab Med. 2000;20:303-343.
69. De Boer MA, Peters LA, Aziz MF, et al. Human papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and The Netherlands. Gynecol Oncol. 2004;94:488-494.
70. Tornesello ML, Duraturo ML, Salatiello I, et al. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol. 2004;74:117-126.
71. Sahebali S, Depuydt CE, Segers K, et al. P16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer. 2004;108:871-876.
72. Nieh S, Chen SF, Chu TY, et al. Expression of p 16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol. 2003;91:201-208.